Table 2. Six-Month Outcome Rates Among People Treated With Methadone and Buprenorphine/Naloxone Prior to the COVID-19 Pandemic.
| Outcome | No. of individuals (weighted % per person-year)a | |||||||
|---|---|---|---|---|---|---|---|---|
| Methadone cohorts | Buprenorphine/naloxone cohorts | |||||||
| Daily dispensed cohort | 5-6 Take-home dose cohort | Daily dispensed cohort | 5-6 Take-home dose cohort | |||||
| Increased | No change | Increased | No change | Increased | No change | Increased | No change | |
| Total cohort size | 2865 | 2987 | 5758 | 5252 | 230 | 432 | 2138 | 1635 |
| Opioid overdose | 87 (6.9) | 150 (9.5) | 35 (1.4) | 51 (1.8) | 9 (6.5) | 8 (3.5) | 17 (1.7) | 12 (1.4) |
| Discontinuation of therapy | 574 (51.0) | 806 (63.6) | 370 (14.1) | 456 (19.6) | 74 (85.1) | 151 (93.2) | 255 (26.0) | 230 (30.8) |
| Interruption in therapy | 215 (19.0) | 332 (23.9) | 133 (5.1) | 165 (7.4) | 25 (25.3) | 54 (29.3) | 93 (9.5) | 101 (12.9) |
| All-cause mortality | 20 (1.5) | 21 (1.3) | 27 (0.8) | 28 (1.1) | ≤5b | ≤5b | 8 (0.8) | 7 (0.8) |
| Opioid-related death | 9 (0.6) | 8 (0.5) | ≤5b | 9 (0.3) | ≤5b | ≤5b | ≤5b | ≤5b |
| COVID-19 diagnosis | ≤5b | ≤5b | ≤5b | ≤5b | 0 | ≤5b | 6 (0.5) | ≤5b |
a
Weighted by inverse probability of treatment weights.
b
Institutional policy requires suppression of counts less than 6.